Triamcinolone acetonide (TAC) is the most commonly used intralesional corticosteroid for the treatment of keloids and is considered to be the first line therapy for the treatment of keloids. 7 TAC is used in different concentrations ranging from 10 to 40mg/ml. Different studies recommend different intervals between successive injections and the number of injections may vary from four to eight. 8 Intralesional injection TAC 40mg/ml is more commonly used, as the concentration of 40mg/ml is very effective in controlling keloid. However Local side effects such as dermal atrophy, telengiectasia, hypopigmentation and pain at the site of injection due to TAC 40mg/ml are common. Pain can be avoided by use of topical anesthesia and/or regional injections of local anesthetic around the scars. 9 Hypopigmentation is not a problem in non-pigmented western skin but is significant in pigmented skin.
Aim was to study the efficacy and the adverse effect of intralesional injection triamcinolone acetonide in treatment of keloid, in concentration of 20mg/ml.
METHODS
The study was carried out on 25 patients in Dermatology OPD of a medical college hospital in North India from November 2015 to May 2017 (one year and six months). Patients of keloid of either gender, in the age group 11 to 55 years, were included in the study. Patients with local infection, immune-compromise, pregnancy or lactation and those who had received treatment for keloid during previous 6 months were excluded. Sample size was calculated on the basis of decrease in volume of the keloid. 10 Injection Triamcinolone acetonide 20mg/ml (TAC 20) was injected intralesionally at an interval of 3 weeks, for a total of 6 sittings over a period of 18 weeks. Injection Triamcinolone acetonide 40mg/ml was diluted using lignocaine with adrenaline, in equal proportions, to get a final concentration of 20mg/ml. The lesion was infiltrated with the drug suspension, using a disposable insulin syringe and 26-gauge needle, till complete and uniform blanching of the lesion, was achieved. The subject was not administered any sedation or analgesia prior to the injection.
The details of the subject including the Fitzpatrick skin type, duration, site, number and parameters such as height, pliability, vascularity and pigmentation of the keloid assessed on Vancouver Scar Scale (VSS), were recorded in a predesigned "Case record form." VSS was assessed before treatment and three weeks after completion of the treatment.
VSS is a validated and widely used tool to document a change in appearance of the scar, in clinical practice and research. [11] [12] [13] Parameters of the keloid such as vascularity, pliability, pigmentation and height are assessed, in order to determine the score. The score allotted for pliability is from 0 to 5, score for height and vascularity from 0 to 3 and for pigmentation from 0 to 2, to give a maximum possible score of 13. The decreasing mean value of the total score indicates clinical improvement, in the scar.
Scar height was measured with calipers, and scar pliability assessed by palpation; scar vascularity rated by visual inspection, and the rate of refill, after blanching it.
Blanching was achieved by a transparent plastic sheet with VSS score sheet, pasted on it. Scar pigmentation was assessed after blanching and comparing the scar color with the surrounding skin. 13 The percentage reduction in VSS was graded according to the Quartile score with ≤25% reduction in VSS graded as Poor, 26-50% reduction as Good, 51-75% reduction Very good and >75% reduction as Excellent response.
Data was analyzed using Statistical Package for Social Sciences (SPSS) version 21.0. Wilcoxon signed rank was used to assess the outcome and 'p' value less than 0.05 was considered to be a statistically significant change.
RESULTS
A total of 25 subjects of keloid of either gender, were treated with intralesional injection of triamcinolone acetonide 20mg/ml (TAC-20). All the 25 subjects completed the study. Male were 52%, female 48% and the mean age was 31.76±13.08 years. Family history of keloids was present in 4 (16.0%). The majority (60.0%) of the subjects had Fitzpatrick Skin type IV. Duration of keloid ranged from 1 to 36 months with a median duration of 7 months. The majority (92%) had one or two keloids and 2 (8%) of the subjects had more than three keloids. The majority (90%) of keloids were either on the chest or shoulders. Physician rated outcome was 'Very good' to 'Excellent' in 18 (72%) and 'Good' in 5 (20%) subjects. There were 2 (8%) cases in which outcome was evaluated as 'Poor'. Pain was the most common adverse effect as reported by 21 (84%) patients. Hypopigmentation was observed in 11 (44%), telengiectasia in 4 (16%), and dermal atrophy in 3 (12%) of the subjects (Table 6 ). 15 Corticosteroids seem to be effective as they diminish collagen and glycosaminoglycan synthesis, inhibit fibroblast growth, enhance collagen and fibroblast degeneration and have powerful anti-inflammatory effect. [4] [5] [6] The anti-inflammatory effect of TAC in addition to inhibition of collagen and glycosaminoglycan synthesis, and degeneration of fibroblast/collagen might be giving it an edge, however the drug causes local adverse effects such as dermal atrophy, telengiectasia and hypopigmentation in large number of patients.
Inability to measure amount of drug used with respect to area as well as thickness of keloid, has been a major limitation in this study as in most other studies. Consequently, complete blanching of the keloid, was considered to be the end point, for the dose of the drug injected intralesionally.
TAC is cost effective and practical and has become firstline treatment for keloid, in spite of many limitations. Studies have reported that lower dose of TAC, i.e. 20mg/ml reduces the side effects of TAC without jeopardizing the efficacy. [16] [17] [18] In this study, majority of the subjects were in the age group <30 years; males being slightly more than females. Uzair et al and Ahuja et al also observed predominance of keloid in the younger age group. 19, 20 The duration of keloids in majority of subjects was less than 12 months. The majority showed a very good to excellent response conforming observations from studies.
21, 22 The Keloid were found to be most common on the chest (60%), followed by shoulder (20%), arm (18%) and face (10%) similar to observations. 23 In the present study following intralesional TAC 20, a majority (62.79%) of patients of keloids showed significant mean reduction in VSS. The observations were in conformity with that of Uzair et al. 19 The improvement observed was comparable to TAC 40mg/ml used by Chatterjee A and Shanthi M et al. 15, 20 The improvement in keloid with TAC 20 mg/ml was observed to be similar to TAC 40mg/ml used in other studies. 15, 19, 20, 23, 24 Immediate pain at the site of injection was the commonest side effect with TAC 20 as reported by 84% of the subjects. However, the pain was mild, transitory and resolved within few hours, which is attributed to dilution with lignocaine and adrenaline which causes a sustained hypoesthesia and therapeutic effect at the site, locally. Hypopigmentation was observed in 44%, atrophy in 12% and telengiectasia in 16% of the subjects treated by TAC 20; this was comparable to other studies. [25] [26] [27] Manuskiatti et al and Jannati et al using TAC-20, reported hypopigmentation in 20%, atrophy in 10% and telengiectasia in 20% of patients. 23 , 28 Bilal et al using TAC 40mg/ml reported hypopigmentation (29%), atrophy (4%) and telengiectasia (25%). 29 An occurrence of atrophy in 18% of cases was from studies. 20 In the present study with TAC 20, hypopigmentation was observed in 44 % of the subjects. The incidence of hypopigmentation in the study was much higher as compared to other studies probably because all subjects in this study, were of Fitzpatrick skin type IV and V. Most other studies do not mention the skin phototype of the subjects.
Limitations of the study includes therapeutic effect of injection TAC was studied over a period of only 18 weeks for a patient, which may be inadequate. Post treatment follow up of patient should be of a longer period to judge the recurrence.
CONCLUSION
TAC 20mg/ml gives very good to excellent response in a majority of patients and the improvement is comparable to the result with TAC 40mg/ml as reported by other workers. TAC 20 also causes adverse effects such as hypopigmentation, telengiectasia and atrophy. However adverse effects with TAC 20 are less compared to TAC 40. Immediate postoperative pain occurs but is mild and transitory.
